Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Oct;60(10):956–961. doi: 10.1136/ard.60.10.956

Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample

N Wiles 1, D Scott 1, E Barrett 1, P Merry 1, E Arie 1, K Gaffney 1, A Silman 1, D Symmons 1
PMCID: PMC1753385  PMID: 11557653

Abstract

BACKGROUND—Treatment, and therefore outcome, of rheumatoid arthritis (RA) will improve in the next few years. However, improvement in outcome can only be judged against the probability of certain outcomes with current conventional treatment.
AIM—To document the five year outcome of RA in the late 1990s.
SETTING—Norfolk Arthritis Register (NOAR).
DESIGN—Longitudinal observational cohort study.
METHODS—318 patients with recent onset inflammatory polyarthritis recruited by NOAR in 1990-91 completed five years of follow up. Four groups were assessed: the whole cohort, all those referred to hospital, those who satisfied criteria for RA at baseline, and those referred to hospital who satisfied criteria for RA at baseline. Outcome was assessed with a visual analogue scale for pain, the Health Assessment Questionnaire (HAQ), and the Short Form-36 (SF-36).
RESULTS—Of the RA hospital attenders, 50% had a visual analogue scale pain score of 5 cm or less and an HAQ score of 1.125 or less. SF-36 scores were reduced in all domains. Results are presented as cumulative percentages.
CONCLUSIONS—These results can be used for comparison and to set targets for improvement.



Full Text

The Full Text of this article is available as a PDF (248.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Visual analogue scale (VAS) pain score at five years.    

Figure 2  .

Figure 2  

Open in a new tab

Health Assessment Questionnaire (HAQ) scores at five years. IP = inflammatory polyarthritis.

Figure 3  .

Figure 3  

Open in a new tab

Comparison of NOAR SF-36 domain scores with UK population normative data. IP = inflammatory polyarthritis.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Brazier J. E., Harper R., Jones N. M., O'Cathain A., Thomas K. J., Usherwood T., Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992 Jul 18;305(6846):160–164. doi: 10.1136/bmj.305.6846.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eberhardt K. B., Fex E. Functional impairment and disability in early rheumatoid arthritis--development over 5 years. J Rheumatol. 1995 Jun;22(6):1037–1042. [PubMed] [Google Scholar]
  4. Emery P., Breedveld F. C., Lemmel E. M., Kaltwasser J. P., Dawes P. T., Gömör B., Van Den Bosch F., Nordström D., Bjorneboe O., Dahl R. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun;39(6):655–665. doi: 10.1093/rheumatology/39.6.655. [DOI] [PubMed] [Google Scholar]
  5. Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., Verburg K. M., Isakson P. C., Hubbard R. C., Geis G. S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999 Dec 18;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
  6. Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 Feb;23(2):137–145. doi: 10.1002/art.1780230202. [DOI] [PubMed] [Google Scholar]
  7. Hill C. L., Parsons J., Taylor A., Leach G. Health related quality of life in a population sample with arthritis. J Rheumatol. 1999 Sep;26(9):2029–2035. [PubMed] [Google Scholar]
  8. Kirwan J. R., Reeback J. S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986 May;25(2):206–209. doi: 10.1093/rheumatology/25.2.206. [DOI] [PubMed] [Google Scholar]
  9. Kvien T. K., Kaasa S., Smedstad L. M. Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. J Clin Epidemiol. 1998 Nov;51(11):1077–1086. doi: 10.1016/s0895-4356(98)00099-7. [DOI] [PubMed] [Google Scholar]
  10. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  11. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  12. Ruta D. A., Hurst N. P., Kind P., Hunter M., Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol. 1998 Apr;37(4):425–436. doi: 10.1093/rheumatology/37.4.425. [DOI] [PubMed] [Google Scholar]
  13. Smolen J. S., Kalden J. R., Scott D. L., Rozman B., Kvien T. K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 Jan 23;353(9149):259–266. doi: 10.1016/s0140-6736(98)09403-3. [DOI] [PubMed] [Google Scholar]
  14. Symmons D. P., Barrett E. M., Bankhead C. R., Scott D. G., Silman A. J. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol. 1994 Aug;33(8):735–739. doi: 10.1093/rheumatology/33.8.735. [DOI] [PubMed] [Google Scholar]
  15. Talamo J., Frater A., Gallivan S., Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol. 1997 Apr;36(4):463–469. doi: 10.1093/rheumatology/36.4.463. [DOI] [PubMed] [Google Scholar]
  16. Uhlig T., Smedstad L. M., Vaglum P., Moum T., Gérard N., Kvien T. K. The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford) 2000 Jul;39(7):732–741. doi: 10.1093/rheumatology/39.7.732. [DOI] [PubMed] [Google Scholar]
  17. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  18. Wiles N. J., Dunn G., Barrett E. M., Harrison B. J., Silman A. J., Symmons D. P. One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol. 2000 Oct;27(10):2360–2366. [PubMed] [Google Scholar]
  19. Wiles N., Dunn G., Barrett E., Silman A., Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. J Clin Epidemiol. 2000 Oct;53(10):988–996. doi: 10.1016/s0895-4356(00)00189-x. [DOI] [PubMed] [Google Scholar]
  20. Young A., Dixey J., Cox N., Davies P., Devlin J., Emery P., Gallivan S., Gough A., James D., Prouse P. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) 2000 Jun;39(6):603–611. doi: 10.1093/rheumatology/39.6.603. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES